menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Novartis to close 2 MorphoSys sites, lay off 330 staffers

    FIERCE PHARMA

    PharmaEssentia nabs MorphoSys alum for CCO role

    FIERCE PHARMA

    Novartis` $2.9B MorphoSys bet stumbles as safety delays filing

    FIERCE BIOTECH

    MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

    BUSINESSWIRE

    MorphoSys to Delist from Frankfurt Stock Exchange Following Novartis Acquisition

    CONTRACT PHARMA

    MorphoSys And Novartis Plan Merger Squeeze-Out Of Minority Shareholders

    BUSINESSWIRE

    Erasca restructures; Novartis moves to complete MorphoSys deal

    BIOPHARMADIVE

    Novartis Meets Conditions For $68/Share MorphoSys Acquisition

    GLOBENEWSWIRE

    Novartis to buy radiology drug specialist Mariana for $1 billion

    REUTERS

    Morphosys says takeover by Novartis on course after report of drug safety concern

    REUTERS

    MorphoSys AG Reports First Quarter 2024 Financial Results

    BUSINESSWIRE

    MorphoSys`s Pelabresib Myelofibrosis Data in ASCO Oral Session

    ACCESSWIRE

    MorphoSys Boards Recommend Accepting Novartis Takeover Offer

    BUSINESSWIRE

    Novartis tender offer for MorphoSys AG commences

    GLOBENEWSWIRE

    Novartis begins tender offer for MorphoSys

    REUTERS

    MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis

    ACCESSWIRE

    MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results

    BUSINESSWIRE

    German competition regulator clears path for Novartis takeover of MorphoSys

    REUTERS

    Novartis to acquire cancer-centric MorphoSys for $2.9 bln

    PRESS RELEASE

    MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    PRESS RELEASE

    MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3

    BUSINESSWIRE

    MorphoSys marches ahead with plans to file myelofibrosis drug despite mixed PhIII results

    ENDPTS

    MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Improvement

    BUSINESSWIRE

    MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

    BUSINESSWIRE

    MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

    BUSINESSWIRE

    MorphoSys AG Reports 1Q 2023 Financial Results

    BUSINESSWIRE

    MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results

    BUSINESSWIRE

    Invitation to MorphoSys` Full Year Results 2022 Conference Call on March 16

    ACCESSWIRE

    MorphoSys Stops Pre-Clinical Research Programs; To Cut Jobs

    NASDAQ

    MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

    ACCESSWIRE

    MorphoSys CFO Sung Lee exits as shares suffer in market meltdown

    ENDPTS

    Novartis pays $23M cash for preclinical MorphoSys program

    FIERCEBIOTECH

    MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

    BUSINESSWIRE

    MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease

    ACCESSWIRE

    MorphoSys to Share New Data on Pelabresib and Monjuvi in 14 Presentations at ASH

    ACCESSWIRE

    MorphoSys to Share New Data on Pelabresib and Monjuvi®

    PRESS RELEASE

    That secretive ARCH biotech with two antibodies from MorphoSys?

    ENDPTS

    GSK, MorphoSys` Partner, Provides Update on ContRAst PIII Program for Otilimab

    ACCESSWIRE

    MorphoSys Presents Preliminary Results from Phase 1/2 Study of (CPI-0209)

    ACCESSWIRE

    MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales

    ACCESSWIRE

    MorphoSys shows Data from L-MIND Suggesting Response to Treatment with Monjuvi

    BUSINESSWIRE

    MorphoSys appoints Tim Demuth as new Chief R&D Officer

    MORPHOSYS

    MorphoSys Appoints Tim Demuth as New Chief R&D Officer

    BUSINESSWIRE

    MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results

    BUSINESSWIRE

    Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results

    PRESS RELEASE

    MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales for 2022

    ACCESSWIRE

    MorphoSys finds billion-dollar home for unwanted assets

    FIERCEBIOTECH

    I-Mab Partner MorphoSys Announces License Agreements for Felzartamab and TJ210

    PRNEWSWIRE

    MorphoSys and HIBio Enter Into Agreements for Felzartamab and MOR210

    BUSINESSWIRE

    Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi

    BUSINESSWIRE

    MorphoSys Presents Multiple Analyses of the MANIFEST PII Trial for Pelabresib

    BUSINESSWIRE

    MorphoSys to Present New Data on Pelabresib and Monjuviat EHA and ASCO

    BUSINESSWIRE

    MorphoSys AG Reports First Quarter 2022 Financial Results

    BUSINESSWIRE

    MorphoSys AG Reports Q4 and FY 2021 Financial Results

    BUSINESSWIRE

    MorphoSys cuts R&D from Constellation deal to focus on cancer drugs

    MEDCITYNEWS

    MorphoSys and Incyte Announce Additional Real-World Evidence Results RE-MIND2

    BUSINESSWIRE

    MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study

    BUSINESSWIRE

    MorphoSys presents interim results from M-PLACE study with felzartamab

    MORPHOSYS

    MorphoSys to present MANIFEST and RE-MIND2 data hematology-oncology ASH

    MORPHOSYS

    MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months

    MORPHOSYS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.